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Acute kidney injury occurs in up to one third of patients after cardiac surgery and is an 
important contributor for adverse outcome. Previous research has demonstrated the benefit 
of a bundle of preventive measurements to reduce AKI in a subgroup of patients with high 
risk for AKI development. Urinary stress biomarkers [TIMP-2]*[IGFBP7] are used to identify 
these patients who are at risk for AKI. The trial aims to investigate the potential discrepancy 
between biomarker results and clinical estimation of occurrence of AKI on ICU in clinical 
practice. 
 
Methods and analysis: 
We plan to include 100 adult patients after cardiac surgery with cardiopulmonary bypass in a 
prospective, single center clinical trial. After cardiac surgery, different type of healthcare 
professional in ICU will provide a prediction of AKI occurrence and severity in the next 48 
hours by filling in a questionnaire just before and after [TIMP-2]*[IGFBP7] biomarker 
analysis. Primary, this trial investigates the potential discrepancy in AKI prediction between 
clinical estimation by healthcare providers, biomarker results, and previous described score 
systems. Secondly, the impact of knowledge of the biomarker result on the quality of 
prediction by healthcare providers will be evaluated. 
 
Ethics and dissemination: 
This prospective, single center study has been approved by the medical ethical committee of 
the Ghent University Hospital (28
th
 May 2019, trial registration number B670201939991). 
Informed consent was obtained for patients and healthcare providers.  
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Summary strength and limitations 
- Influence of knowledge of a kidney biomarker on healthcare providers’ assessment of 
risk for AKI in clinical setting 
- Different types of healthcare providers with various expertise  
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Acute kidney injury (AKI) occurs in up to one third of patients after cardiac surgery, and is an 
important contributor for morbidity, mortality, and Health care utilization 
1
. In  2012, The 
Kidney Disease: Improving Global Outcomes (KDIGO) guideline provided a set of 
measurements to prevent AKI in high risk patients, the so-called “AKI Bundle” 
2
. 
Subsequently, Meersch et al showed in a single centre randomized trial a significant 
decrease in occurrence of AKI in a cohort of cardiac surgery patients when such an AKI 
bundle was used 
3
. To evaluate the effect of implementing the bundle in a multinational 
setting, a multicentre randomised controlled trial was performed by Zarbock et al (PrevAKI2) 
4
. In the PrevAKI trials, high risk patients for AKI were identified by the Nephrocheck® Test 
using a point-of-care device (Astute 140 meter) that provides results within 20 minutes 
(Astute Medical®). This test measures the two urine stress biomarkers tissue inhibitor of 
metalloproteinases-2 and insulin-like growth factor-binding protein 7 and reports these as 
the product of these biomarkers ([TIMP-2]*[IGFBP7]) 
5
. A cut-off of 0.3 is used to identify 
patients at high risk for AKI, and a value >2 identifies patients at highest risk for AKI 
6
.  
In cardiac surgery patients, healthcare providers typically assess the risk for AKI by 
integrating information from diverse sources such as the information on previous health 
status of the patient, detailed information on the type of surgery, and the clinical course 
during surgery and the first few hours after ICU admission.  This clinical AKI risk assessment 
is also influenced by experience and clinical expertise. There are also several scoring systems 
for prediction of occurrence of AKI after cardiac surgery.  It is unclear whether the 
information on kidney stress provided by the NephroCheck® is complimentary to the 
assessment based on clinical expertise. We therefore want to investigate in this PREDICTAKI 
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study the clinical risk assessment for AKI and compare this to the NephroCheck® AKI risk and 
scoring systems. In addition, we will evaluate the predictive performance of scoring systems 





Objectives and Aims: 
Aim 1: To investigate if healthcare providers are able to predict the occurrence of AKI and 
renal replacement therapy (RRT) 4-h after ICU admission  
Null hypothesis: Healthcare providers are equal in predicting the occurrence of AKI and RRT 
within 48 hours after cardiac surgery compared to the biomarker [TIMP-2]*[IGFBP7] and 
scoring systems. 
AIM 2: To investigate the impact of knowledge of the biomarker [TIMP-2]*[IGFBP7] 
 result on the prediction of healthcare providers 
Hypothesis 2: The prediction of healthcare providers will improve with the knowledge of the 
biomarker results. 
AIM 3: Investigate if subgroups of healthcare providers are better in prediction of AKI and 
RRT at 48-h after cardiac surgery 
Hypothesis 3: Physicians are better in prediction of AKI and RRT at 48-h after surgery in 
comparison to ICU nurses  
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Methods and analysis 
Design and setting 
This is a prospective, observational, single centre trial performed at the Ghent University 
Hospital. 
 
Patient and public involvement 
Patients and public were not involved in the research design of the study. Study results will 
be published as an open access publication.  
 
Participants  
Patients are eligible for inclusion if they are scheduled for cardiac surgery with the use of 
cardiopulmonary bypass, age is between 18 and 90 years and when written consent is 
obtained. Patients will be excluded if there is pre-existing AKI (≥ stage 1), need for cardiac 
assist devices (such as intra-aortic balloon pump (IABP), extracorporeal membrane 
oxygenation (ECMO), left ventricular assist device (LVAD), right ventricular assist device 
(RVAD)), when patients are pregnant or breast feeding, when there is known nephritis, 
interstitial nephritis or vasculitis, when there is chronic kidney disease (CKD) with eGFR 
below 20ml/min/1.73 m
2
, when there is need for RRT, or when the patient received a kidney 
transplant in the preceding 12 months. 
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Co-enrolment in PrevAKI trial. 
The PrevAKI trial investigates the implementation of a bundle of supportive measures to 
prevent AKI in high risk patients in a multicentre setting. (Principal investigator: Prof. Dr. A. 
Zarbock, University Hospital Muenster, Germany, Belgium ethical committee project 
number: B670201734684). Co-enrolment in both PrevAKI and PREDICTAKI trials is allowed 
and the biomarker results will be used in both trials. 
 
Consent process 
Written consent for the PREDICTAKI trial will be obtained according to the requirements of 
the local ethical committee. Consent will be asked to both patients and healthcare providers 
participating in the trial. Information will be given about the purpose of the trial, the design, 
the aim, its benefits as well as potential risks. Because this trial only involves one urine 
sample taken from the urinary catheter which is routinely placed for cardiac surgery, study 
related risks are absent. The consent will only be taken if the patient is able to give written 
consent, the day before surgery. All data will be kept and stored in pseudo-anonymised 
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Patients eligible for participation are asked for written consent after being thorough 
informed about trial purpose, design, aim, benefits and risks. Consent is asked one day 
before surgery. 
Four hours after cardiopulmonary bypass for cardiac surgery, one urine sample is collected 
from the urinary catheter. [TIMP-2]*[IGFBP7] will be measured using the Nephrocheck® Test 
(Astute Medical). During Nephrocheck analysis, which takes about 20 minutes, 
questionnaires are filled in by several types of healthcare providers (HCP): 1. an intensivist, 
2. a medical doctor in training on ICU, 3. an ICU nurse, and 4. a nephrologist (see figure 1 and 
2). The first three HCPs are taking care of the patients, whereas the nephrologist is consulted 
almost simultaneously for risk assessment. Six AKI or renal replacement therapy (RRT) 
prediction scores are calculated: Cleveland Clinical score, Crate score, Mehta score, Murphy 
score, Ng Score and the ‘AKI predictor’ score 
7-12
. The results of these scores are not available 
for the HCPs when they fill out the questionnaire. 
The questionnaire consists of 4 questions and answers are according to a 9 elements Likert 
scale (figure 2).  
When the Nephrocheck® Test result is known, the result is presented to the HCPs and they 
are asked to again predict AKI, with the knowledge about the biomarker result.  
All HCPs receive a short explanation (written and oral) on the Nephrocheck® Test result: a 
value ≥ 0.3 (ng/ml)
2
/1000 identifies patients with a high risk for AKI. 
Kidney function will be followed up for 48 hours after ICU admission (See figure 1 Trial 
workflow). Demographic patient data will be collected. 
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Primary outcome  
- Prediction of AKI and RRT 48 hours after ICU admission by HCPs, the NephroCheck® 
and 6 AKI scoring systems.    
Secondary outcomes: 
- the influence of knowledge of the NephroCheck® test result, on the assessment of 
AKI risk by HCPs.  
- the difference of AKI prediction by of several types of HCPs. 
 
Sample size 
Since there are to the best of our knowledge no comparable studies on this topic, we could 
not perform a power calculation. We also acknowledge that clinical assessment of risk for 
AKI post cardiac surgery will be highly influenced by HCPs expertise and will therefore 
possibly vary in different settings. This pilot study is therefore designed to gain more 
knowledge on this specific topic, so that these data can be used to design future prospective 
multicentre studies.  We arbitrarily set the number of patient inclusions for this trial at 100. 
For each patient, 4 HCPs will fill in a questionnaire before and after biomarker knowledge 
resulting in 800 questionnaires. Each questionnaire contains 4 predictions, resulting in a 
total of 3200 AKI related predictions. 
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Statistical analysis  
HCPs will fill in a paper questionnaire. These questionnaires and study specific data gathered 
by our electronic ICU patient data management system (PDMS) (Centricity Critical Care®, 
General Electric, USA) will be prospectively collected by using REDCap electronic data 
capture tools hosted at Ghent University. 
Predictive ability will be evaluated with the receiver operator characteristic curve (ROC) and 
quantified by the area under the curve (AUC). AUC-ROC is defined as excellent when AUC-
ROC ≥0.900 ; good: 0.800 ≤ AUC-ROC ≤0.899; fair: 0.700 ≤ AUC-ROC ≤0.799; poor: 0.600 ≤ 
AUC-ROC ≤ 0.699; and failed when AUC-ROC < 0.60.  Calibration of the predictions will be 
evaluated. Interrater reliability will be investigated by calculation of percentage agreement, 
interclass correlation coefficient and Kappa statistics. 





percentile) and compared using the Mann-Whitney U and Kruskal-Wallis tests. Qualitative 
parameters will be reported as number and percentage and compared using the Chi-square 
test.  Two-sided P values of <0.05 will be considered statistically significant.  
 
Ethics and dissemination: 
This prospective, single center study has been approved by the medical ethical committee of 
Ghent University Hospital (28
th
 May 2019, B670201939991). Informed consent was obtained 
for patients and healthcare providers. Trial oversight will be performed by the Health, 
Innovation and Research institute of Ghent University Hospital (HIRUZ). 
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There was no financial support for this study.   
When patients are co-enrolled in the PrevAKI trial, Nephrocheck® device and cartridges were 
provided by this study.  
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Trial status 
Recruitment started in 1
st
 July 2019 and estimate to complete the study in August 2020. 
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 





1. Vandenberghe W, Gevaert S, Kellum JA, et al. Acute Kidney Injury in Cardiorenal Syndrome 
Type 1 Patients: A Systematic Review and Meta-Analysis. Cardiorenal Med. 2016;6(2):116-28. 
2. kellum JA, Aspelin P, Barsoum RS. KDIGO clinical practice guideline for acute kindney injury 
2012. Kindney Int Suppl. 2012(2):1-138. 
3. Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by 
implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI 
randomized controlled trial. Intensive Care Med. 2017;43(11):1551-61. 
4. Kullmar M, Massoth C, Ostermann M, et al. Biomarker-guided implementation of the KDIGO 
guidelines to reduce the occurrence of acute kidney injury in patients after cardiac surgery (PrevAKI-
multicentre): protocol for a multicentre, observational study followed by randomised controlled 
feasibility trial. BMJ Open. 2020;10(4):e034201. 
5. Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest 
biomarkers in human acute kidney injury. Critical care (London, England). 2013;17(1):R25. 
6. Hoste EA, McCullough PA, Kashani K, et al. Derivation and validation of cutoffs for clinical use 
of cell cycle arrest biomarkers. Nephrol Dial Transplant. 2014;29(11):2054-61. 
7. Birnie K, Verheyden V, Pagano D, et al. Predictive models for kidney disease: improving global 
outcomes (KDIGO) defined acute kidney injury in UK cardiac surgery. Crit Care. 2014;18(6):606. 
8. Flechet M, Guiza F, Schetz M, et al. AKIpredictor, an online prognostic calculator for acute 
kidney injury in adult critically ill patients: development, validation and comparison to serum 
neutrophil gelatinase-associated lipocalin. Intensive Care Med. 2017;43(6):764-73. 
9. Jorge-Monjas P, Bustamante-Munguira J, Lorenzo M, et al. Predicting cardiac surgery-
associated acute kidney injury: The CRATE score. J Crit Care. 2016;31(1):130-8. 
10. Mehta RH, Grab JD, O'Brien SM, et al. Bedside tool for predicting the risk of postoperative 
dialysis in patients undergoing cardiac surgery. Circulation. 2006;114(21):2208-16; quiz  
11. Ng SY, Sanagou M, Wolfe R, et al. Prediction of acute kidney injury within 30 days of cardiac 
surgery. J Thorac Cardiovasc Surg. 2014;147(6):1875-83, 83 e1. 
12. Thakar CV, Arrigain S, Worley S, et al. A clinical score to predict acute renal failure after 
cardiac surgery. J Am Soc Nephrol. 2005;16(1):162-8. 
 
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
The copyright holder for this preprintthis version posted July 17, 2020. .https://doi.org/10.1101/2020.07.13.20148643doi: medRxiv preprint 

















Legend: AKI; acute kidney injury;Tissue inhibitor of metalloproteinases-2 and insulin-like growth factor-binding protein 7 ([TIMP-2]*[IGFBP7]); 
ICU, intensive care unit. 
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Figure 2: Questionnaire 
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